Peptron

087010.KQ

100.90 USD

-36.71

-26.68%

Overview

Last close

100.90 usd

Market cap

1.55B usd

52 week high

262.86 usd

52 week low

70.12 usd

Target price

25.72 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

581.542

Price/Book Value

26.1202

Enterprise Value

2.45B usd

EV/Revenue

702.2613

EV/EBITDA

-17.5233

Key financials

Revenue TTM

4.27M usd

Gross Profit TTM

3.28M usd

EBITDA TTM

-7.89M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

108.54M usd

Net debt

11.61M usd

About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.